PMID- 26617874
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20220330
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 8
IP  - 9
DP  - 2015
TI  - Down-regulation of PAX6 by promoter methylation is associated with poor prognosis 
      in non small cell lung cancer.
PG  - 11452-7
AB  - BACKGROUND: Promoter methylation is an alternative mechanism of gene silencing in 
      human tumorigenesis. Although a number of methylated genes have been found in non 
      small cell lung cancer (NSCLC), useful methylation markers for early prognostic 
      evaluation of NSCLC remain largely unknown. METHODS: Using methylation-specific 
      PCR (MSP), we examined promoter methylation status of PAX6 gene, and explored 
      their association with clinical features in NSCLC via chi-square test. NSCLC 
      patient survival was assessed by Kaplan-Meier analyses and a Cox proportional 
      hazard model was employed for multivariate analyses. RESULTS: The methylation 
      level of PAX6 gene was higher in tumor tissues than that in normal tissues. In 
      addition, PAX6 promoter methylation showed a very significant correlation with 
      differentiation (P = 0.002), distant metastasis (P = 0.024), and TNM stage (P = 
      0.002). PAX6 gene promoter hyper-methylation was found to be significantly 
      associated with poor overall survival (P = 0.018) and to serve as an independent 
      marker for prognosis using multivariate Cox regression analysis (HR: 2.254, 95% 
      CI: 1.088-4.667, P = 0.029). CONCLUSION: We found that PAX6 gene was specifically 
      methylated in NSCLC, and demonstrated the effect of promoter methylation of PAX6 
      gene on clinical outcome in NSCLC, indicating the methylated PAX6 may be useful 
      biomarkers for prognostic evaluation in NSCLC.
FAU - Zhang, Xiangxian
AU  - Zhang X
AD  - Xiangya Hospital of Central South University China.
FAU - Yang, Xiao
AU  - Yang X
AD  - Xiangya Hospital of Central South University China.
FAU - Wang, Junling
AU  - Wang J
AD  - Department of Seven-year Clinical Medicine, Grade 2011, Zhengzhou University 
      China.
FAU - Liang, Tiansong
AU  - Liang T
AD  - Radiotherapy and Severe Tumor Institution, Zhengzhou University China.
FAU - Gu, Yue
AU  - Gu Y
AD  - Department III of Radiation Oncology, The First Affiliated Hospital of Zhengzhou 
      University China.
FAU - Yang, Daoke
AU  - Yang D
AD  - Department III of Radiation Oncology, The First Affiliated Hospital of Zhengzhou 
      University China.
LA  - eng
PT  - Journal Article
DEP - 20150901
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (PAX6 Transcription Factor)
RN  - 0 (PAX6 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/analysis/genetics
MH  - Carcinoma, Non-Small-Cell Lung/genetics/mortality/*pathology
MH  - DNA Methylation/*genetics
MH  - Disease-Free Survival
MH  - Down-Regulation
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/*genetics
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Lung Neoplasms/genetics/mortality/*pathology
MH  - Male
MH  - Middle Aged
MH  - PAX6 Transcription Factor/*biosynthesis/genetics
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - Promoter Regions, Genetic/genetics
MH  - Proportional Hazards Models
PMC - PMC4637690
OTO - NOTNLM
OT  - Non-small cell lung cancer
OT  - PAX6
OT  - methylation
OT  - prognosis
EDAT- 2015/12/01 06:00
MHDA- 2016/12/15 06:00
PMCR- 2015/09/01
CRDT- 2015/12/01 06:00
PHST- 2015/04/30 00:00 [received]
PHST- 2015/06/22 00:00 [accepted]
PHST- 2015/12/01 06:00 [entrez]
PHST- 2015/12/01 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
PHST- 2015/09/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2015 Sep 1;8(9):11452-7. eCollection 2015.